Both peptides address obesity and type 2 diabetes, conditions that affect hundreds of millions of people worldwide
Understanding the options helps patients make informed decisions aligned with their expectations and recovery capabilities
Weight loss results and benefits Retatrutide is still going through clinical trials , but early results are looking very promising
One such promising weight-loss treatment, Retatrutide, is currently under investigation
The Role of Wraparound Care UK clinical guidelines, including those from the British Obesity and Metabolic Surgery Society (BOMSS), stress the importance of wraparound care
Obesity For weight loss, healthcare professionals may prescribe GLP-1 agonists for people with an initial BMI of 30 or higher or people who have a BMI of 27 or higher and at least one weight-related health condition, such as: type 2 diabetes prediabetes high blood pressure high cholesterol heart disease nonalcoholic fatty liver disease obstructive sleep apnea polycystic ovary syndrome Typically, healthcare professionals only prescribe these medications after someone has tried other weight loss methods, such as diet and exercise, without success
